Biosimilar drug development involves many of the same steps that a biologic drug goes through but with a different focus. 

Meditation programs are popping up across Canada – and for good reason.   This centuries-old practice, also known as mindfulness, is one of the best tools for our health, well-being, and happiness.  Research shows a daily meditation practice reduces stress, depression, and inflammation while improving sleep, fatigue, and menopausal symptoms in women who have a breast cancer diagnosis.   Additionally, studies connect meditation and an enhanced immune function.  These are all important considerations when you’ve had a breast cancer diagnosis.

I was diagnosed with breast cancer in February 2016. My understanding of the language of breast cancer that allowed me to fully comprehend my diagnosis and treatment options, came long after the news. Long after the radiologist told me that my mammogram was “highly suspicious for cancer.” Long after the surgeon doing my breast biopsy spelled out that I had a mass in my left breast, at least two enlarged lymph nodes, and was facing “a very difficult year.” Using that language now, I had locally advanced, hormone responsive, HER2 negative, stage 2, invasive ductal carcinoma: T2N1. After that difficult year (and more), my cancer is in remission.

Biosimilar therapies have already been in use in Canada for a few years, mostly in the chronic disease and supportive care settings. But soon they will be used for treating cancer as well. There isn’t a lot of information about these new oncology biosimilars and it’s important that breast cancer patients are aware of how their treatment plans may be impacted by these new therapies. We explore some of the emerging biosimilar therapies that will be used to treat cancer patients soon.

We are all familiar with generics.  The exact copy of the known chemical formula used in the original medicine is what constitutes the generic form of any medicine.  There are multiple reasons why generics are able to be mass produced at a lower cost.  An important step includes manufacturers of generics having to provide proof that their version is an exact copy of the chemical formula of the original medicine and that when used in healthy individuals, the metabolism remains very similar to the original compound.  This shortened pathway of getting approved from Health Canada or a similar regulatory agency ensures less economic burden to manufacturers and provides the obvious advantage of a significantly lower price, as well as improved accessibility for patients.

On May 1^st and 2^nd I had the pleasure of representing CBCN at an Advisory Committee meeting for the Inuit Cancer Project lead by Pauktuutit Inuit Women of Canada in Iqaluit, NU. This meeting gave those involved in the project an opportunity to meet face to face to discuss an overview of the project, how it was proceeding, along with an update of recent activities and roundtable discussions. These roundtable discussions included opportunities to speak about lessons learned, ways to build community engagement, community capacity and next steps.

As a breast cancer survivor and board member of CBCN, I am very interested in how biosimilars will be used in breast cancer treatment in Canada. While not commonly understood today, biosimilars will soon be a household discussion among breast cancer patients.   As patients, it is important for us to know how biosimilars will be used to treat cancer, especially if they are going to be used as effective alternatives to brand name treatments. Here are some of the points that I think are important for us, as patients, to consider.

Earlier this month, the annual meeting for the American Society of Clinical Oncology was held in Chicago. Here, key research developments in every area of cancer care are shared with oncology professionals from around the world. We’ve compiled the top breast cancer highlights to come out of this year’s ASCO 2018 conference:

I have been living with metastatic breast cancer for over eight years. While I am usually averse to using battle analogies for living with and dying from cancer, finding the best care has required a fight, considerable perseverance, and hard work. Fortunately, my ER+/PR+ tumours (pleura/liver/lymph) have responded well, but not great, to hormonal therapies.  I’m onto my seventh line of treatment. 

Dense breasts are common in Canadian women, affecting about 3.4 million women. Having dense breasts makes it harder to detect cancer on a mammogram yet women are not being told.